ProCE Banner Activity

PARP Inhibitors in Prostate Cancer: Improving Patient Outcomes Through Precision Therapy


Learn how the APP’s role is evolving in caring for patients receiving PARP inhibitors for prostate cancer, from determining eligibility to patient counseling to managing treatment-related adverse events.

Released: April 19, 2023



Frank dela Rama

Frank dela Rama, RN, MS, AOCNS, AGN-BC

Clinical Nurse Specialist, Oncology/Geonomics
Palo Alto Medical Foundation
Sutter Health
Palo Alto, California 

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner


Supported by educational grants from AstraZeneca, and Merck Sharp & Dohme LLC.


Merck Sharp & Dohme, LLC